Melanoma

Hospital Medicine

Volumn 61, Issue 2, 2000, Pages 103-107

  Newton Bishop, Julia A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; DYSPLASTIC NEVUS; FEMALE; GENETICS; HUMAN; MALE; MELANOMA; PATHOLOGY; PEDIGREE; PIGMENTED NEVUS; PROGNOSIS; REVIEW; RISK FACTOR; SKIN TUMOR;

AGE DISTRIBUTION; DYSPLASTIC NEVUS SYNDROME; FEMALE; HUMANS; MALE; MELANOMA; NEVUS, PIGMENTED; PEDIGREE; PROGNOSIS; RISK FACTORS; SKIN NEOPLASMS;

EID: 0034137640     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.2000.61.2.1273     Document Type: Article

References (15)

1. Armstrong BK, Kricker A (1993) How much melanoma is caused by sun exposure. Melanoma Rex 3(6): 395-401
2. Balch CM, Soong S-J, Shaw HM, Milton GW (19X5) An analysis of prognostic factors in 4000 patients with cutairous melanoma. In: Balch CM, Milton GW. eds. Cutamms Melanoma. Lippincott, Philadelphia: 321-51
3. Buzaid AC Boss MI, Balch CM et al (1997) Critical analysis of the currnt A.ICC staging system for cutaneous melanoma amnroposal of a new staging system. J Clin Oncol 15: 1039-1
4. Bystryn J-C. Shapir. RL, Harris M, Roses DF, Oratz R (1996) Use of vacvines in treatment of malignant melanoma. Clin Dermutol 14(4): 337-41
5. Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G (1996) Regulation of p 16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 16: 859-67
6. Mersey P (1994) Melanoma vaccines. Current status and future prospects. Drugs 47: 373-82
7. Kamb A, Gruis N, Weaver-Feldhaus J et al (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-40
8. Mackie RM (1988) Clinical and histological evidence of an association between benign melanocytic naevi and malignant melanoma. Pigment Cell 9: 48-58
9. Morton D, Wen D, Wong J et al (1992) Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127: 392-9
10. Newton Bishop J (1996) Current immunotherapy for melanoma. Cancer Sitrvevs 26: 321-33
11. Newton Bishop J, Harland M. Bennett D et al (1999) Mutation testing in melanoma families: INK4A. CDK4 and INK4D. Br J Cancer 80: 295-300
12. Newton Bishop J, Harland M. Wachsmulh R et al (2000) Genotype/phenotype studies of familial melanoma families. J Invent Derntatol in press
13. Newton JA. Bataille V. Griffiths K et al (1993) How common is the atypical mole syndrome phenotype in apparently sporadic melanoma? J Am Acad Dermatol 29: 989-96
14. Uhrbom L. Nister M. Westermark B (1997) Induction of senescence in human malignant glioma cells by p16INK4A. Oncogene 15: 505-14
15. Zuo L. Weger J, Yang Q et al (1996) Germline mutations in the p!61NK4a binding domain of CDK4 in familial melanoma. Nature Gener 12(1): 97-9